Key result
Complex PCI shows similar 2-year target lesion failure to noncomplex PCI with zotarolimus-eluting stents.
Why the study?
Conflicting trial results on the ability of drug-eluting stents to prevent target lesion revascularization in complex lesions have driven studies into the safety and efficacy of newer-generation DES in complex PCI.
Answers are grounded in this paper and cite their sources.
Supports comparable outcomes in complex PCI; leaves open need for randomized confirmation before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kenichiro Otsuka (2021) conducted an editorial in Obstructive coronary artery disease undergoing percutaneous coronary intervention with zotarolimus-eluting stents (n=926). Complex PCI with zotarolimus-eluting stents (Resolute Integrity) vs. Noncomplex PCI with zotarolimus-eluting stents was evaluated on 2-year target lesion failure (TLF) (HR 1.157, 95% CI 0.476-2.808, p=0.748). Complex PCI with zotarolimus-eluting stents showed no significant difference in 2-year target lesion failure compared to noncomplex PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: